Welcome
Support Centre
13 October 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Optimisation of defibrillation for ventricular fibrillation: the use of low tilt waveforms for the defibrillation of ventricular fibrillation
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN06531828
Date ISRCTN assigned30/07/2007
Local reference number(s)RGHT000386
Public titleOptimisation of defibrillation for ventricular fibrillation: the use of low tilt waveforms for the defibrillation of ventricular fibrillation
Scientific title
AcronymN/A
Disease/condition/study domainVentricular fibrillation/cardiac arrest
Study hypothesisOverall survival rates from Ventricular Fibrillation (VF) are currently very poor. A more efficient biphasic defibrillator with novel low-tilt technology could improve the chances of terminating VF early thus increasing the chances of survival. The primary aim of this study is to determine whether the use of a defibrillator with a low-tilt biphasic waveform will improve the success of defibrillation of ventricular fibrillation.
Design/methodologyRandomised, controlled, safety and feasability study
Research ethics reviewThis project has been reviewed and approved by the Office for Research Ethics Committees in Northern Ireland (ORECNI) on the 8th November 2006 (ref: 06/NIR02/108).
Countries of trialUnited Kingdom
Participants - inclusion criteriaAll adult patients in cardiac arrest with ventricular fibrillation as the identified rhythm.
Participants - exclusion criteriaPatients with existing 'Do not resuscitate' orders.
Patient information material
Anticipated start date01/12/2006
Anticipated end date30/11/2007
Status of trialCompleted
Target number of participants110
InterventionsThis will be a safety and feasibility study which aims to show equivalence in the removal of ventricular fibrillation during cardiac arrests between a novel low-tilt defibrillating device and the standard-tilted defibrillator currently in use in the trust (Philips Agilent Heartstart XL).

Standard-tilted biphasic defibrillators are currently available on all hospital wards, to the cardiac arrest team and the physician-led cardiac ambulance. Randomisation will occur on a daily basis between the novel low-tilt device and the standard-tilted defibrillator. The randomised device will be made available to the cardiac arrest team, in the coronary care unit and also to the physician-led cardiac ambulance.

It will not be possible to blind those staff delivering the defibrillating shocks to the device in use due to their appearances.

Patients found to be in VF will receive treatment according to the resuscitation guidelines issued by the Resuscitation Council (UK) 2005. The standard-tilted device will deliver shocks at 150 J and the low-tilt device 120 J. Following any three unsuccessful shocks, a rescue shock of 200 J will be used from the standard-tilted defibrillator.

All shocks will be delivered via standard self-adhesive pads which have previously been validated for clinical use. Defibrillating shocks will be delivered by a doctor, nurse or resuscitation officer who is fully trained in advanced life support.

The following non-invasive parameters will also be recorded and analysed:
1. Time from collapse to arrival of emergency services
2. Time to first shock
3. Whether Cardio-Pulmonary Resuscitation (CPR) is performed pre-shock
4. Any delays in shock delivery
5. Duration of arrest
6. Drugs administered
7. Patient demographics
7. Aetiology of VF (where possible)

There will be no follow up of any patients. Patients will only be included in the study at the time of required defibrillation.
Primary outcome measure(s)The primary endpoint of the study will be termination of ventricular arrhythmia for greater than or equal to five seconds following shock delivery. This will be determined by analysis of the defibrillator Electrocardiogram (ECG) tracing post-cardiac arrest.
Secondary outcome measure(s)No secondary outcome measures
PublicationsDarragh KM, Doyle C, Walsh SJ, Allen JD, Adgey AAJ, Anderson J, Manoharan G. A novel low tilt biphasic waveform is more efficacious than a standard waveform in the defibrillation of VF. (Abstract) Journal of Electrocardiology, 2007. In Press
Sources of fundingThe Heart Trust Fund (UK)
Sponsor nameRoyal Hospitals Trust (UK)
Sponsor detailsRoyal Research Office
Grosvenor Road
Belfast
United Kingdom
BT12 6BA
Sponsor websitehttp://www.belfasttrust.hscni.net/
Contact nameProf Jennifer Adgey
Contact detailsRegional Medical Cardiology Centre
Royal Hospitals
Grosvenor Road
Belfast
United Kingdom
BT12 6BA
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN06531828
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central